LEGN — Legend Biotech Corporation
$4.1B market cap · 0 upcoming readouts tracked
Clinical trial readout dates for Legend Biotech Corporation, compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
In progress, no date published
| Phase 3 (CARTITUDE-6) Newly-diagnosed multiple myeloma (MM) | date not published Enrollment Conclusion |
Target dates already passed
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 2 Ciltacabtagene autoleucel Relapsed/Refractory Multiple Myeloma (R/R MM) | December 31, 2021 Ongoing |
Companies working on similar indications
Discussion
No messages yet. If you follow LEGN, you can start the conversation.
Track LEGN in real time
See live implied volatility for
LEGN and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on LEGN